FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jan Fagerberg

Research Profile

Disorders

Chemicals & Drugs

Anatomy

T-Lymphocytes

Procedures

Co-author Network

Publications

TOP 3
Dag Stockeld; Lars Backman; Sture Falkmer; Ursula Falkmer; Lars Granström; Jan Fagerberg
Response to chemoradiatiotherapy in squamous cell carcinoma of the esophagus: evaluation of some prognostic factors.
Maria Liljefors; Bo Nilsson; Jan Fagerberg; Peter Ragnhammar; Håkan Mellstedt; Jan-Erik Frödin
Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Szilvia Mosolits; Katja Markovic; Jan Fagerberg; Jan-Erik Frödin; Mohammad-Reza Rezvany; Shahryar Kiaii; Håkan Mellstedt; Mahmood Jeddi-Tehrani
T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jan Fagerberg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Dag Stockeld; Lars Backman; Sture Falkmer; Ursula Falkmer; Lars Granström; Jan Fagerberg
Response to chemoradiatiotherapy in squamous cell carcinoma of the esophagus: evaluation of some prognostic factors.
Clinical and experimental gastroenterology 2009;2():41-7.
2005: Maria Liljefors; Bo Nilsson; Jan Fagerberg; Peter Ragnhammar; Håkan Mellstedt; Jan-Erik Frödin
Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
International journal of oncology 2005;26(6):1581-9.
2005: Szilvia Mosolits; Katja Markovic; Jan Fagerberg; Jan-Erik Frödin; Mohammad-Reza Rezvany; Shahryar Kiaii; Håkan Mellstedt; Mahmood Jeddi-Tehrani
T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody.
Cancer immunology, immunotherapy : CII 2005;54(6):557-70.
2004: Szilvia Mosolits; Fiona Campbell; Sergey V Litvinov; Jan Fagerberg; J Scott Crowe; Håkan Mellstedt; Jonathan H Ellis
Targeting human Ep-CAM in transgenic mice by anti-idiotype and antigen based vaccines.
International journal of cancer. Journal international du cancer 2004;112(4):669-77.
2004: Szilvia Mosolits; Katja Markovic; Jan-Erik Frödin; Lena Virving; Carl G M Magnusson; Michael Steinitz; Jan Fagerberg; Håkan Mellstedt
Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(16):5391-402.
2004: Gustav J Ullenhag; Jan Fagerberg; Karin Strigård; Jan-Erik Frödin; Håkan Mellstedt
Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA.
Cancer immunology, immunotherapy : CII 2004;53(4):331-7.
2003: Lotta Hansson; Hodjattallah Rabbani; Jan Fagerberg; Anders Osterborg; Håkan Mellstedt
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma.
Blood 2003;101(12):4930-6.
2002: Szilvia Mosolits; Michael Steinitz; Ulrika Harmenberg; Ulla Ruden; Emma Eriksson; Håkan Mellstedt; Jan Fagerberg
Immunogenic regions of the GA733-2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma.
Cancer immunology, immunotherapy : CII 2002;51(4):209-18.
2002: Jan-Erik Frödin; Jan Fagerberg; Anna-Lena Hjelm Skog; Maria Liljefors; Peter Ragnhammar; Håkan Mellstedt
MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.
Hybridoma and hybridomics 2002;21(2):99-101.
2000: Håkan Mellstedt; Jan Fagerberg; Jan-Erik Frödin; Anna-Lena Hjelm Skog; Maria Liljefors; Katja Markovic; Szilvia Mosolits; Peter Ragnhammar
Ga733/EpCAM as a target for passive and active specific immunotherapy in patients with colorectal carcinoma.
Annals of the New York Academy of Sciences 2000;910():254-61; discussion 261-2.
1999: Anna-Lena Hjelm Skog; Peter Ragnhammar; Jan Fagerberg; Jan-Erik Frödin; M Goldinger; H Koldestam; Maria Liljefors; Bo Nilsson; Jayant D Shetye; Peter Wersäll; Håkan Mellstedt
Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Cancer immunology, immunotherapy : CII 1999;48(8):463-70.
1999: Håkan Mellstedt; Jan Fagerberg; Anders Osterborg
Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man.
European journal of cancer (Oxford, England : 1990) 1999;35 Suppl 3():S29-32.
1999: Håkan Mellstedt; Jan Fagerberg; Jan-Erik Frödin; L Henriksson; A L Hjelm-Skoog; Maria Liljefors; Peter Ragnhammar; Jayant D Shetye; Anders Osterborg
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.
Current opinion in hematology 1999;6(3):169-75.
1999: Jan Fagerberg; Q Yi; D Gigliotti; Ulrika Harmenberg; U Rudén; B Persson; Anders Osterborg; Håkan Mellstedt
T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma.
International journal of cancer. Journal international du cancer 1999;80(5):671-80.
1999: Szilvia Mosolits; Ulrika Harmenberg; U Rudén; L Ohman; Bo Nilsson; B Wahren; Jan Fagerberg; Håkan Mellstedt
Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma.
Cancer immunology, immunotherapy : CII 1999;47(6):315-20.
1998: A Samanci; Q Yi; Jan Fagerberg; Karin Strigård; G Smith; U Rudén; B Wahren; Håkan Mellstedt
Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen.
Cancer immunology, immunotherapy : CII 1998;47(3):131-42.
1998: Anders Osterborg; Q Yi; L Henriksson; Jan Fagerberg; S Bergenbrant; Mahmood Jeddi-Tehrani; U Rudén; A K Lefvert; Göran Holm; Håkan Mellstedt
Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses.
Blood 1998;91(7):2459-66.
1998: Håkan Mellstedt; Jan Fagerberg; Anders Osterborg
[Vaccination against cancer soon a therapeutic possibility. B-cell tumors, colonic cancer and melanoma may be suitable for this treatment].
Läkartidningen 1998;95(13):1405-10.
1997: Peter Wersäll; Jan Fagerberg; I Ohlsson; U Rudén; J Boethius; Håkan Mellstedt
Induction of a T- and B-cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb-treated patient.
International journal of cancer. Journal international du cancer 1997;73(6):790-4.
1996: A Andersson; Jan Fagerberg; Rolf Lewensohn; Hans Ehrsson
Pharmacokinetics of cisplatin and its monohydrated complex in humans.
Journal of pharmaceutical sciences 1996;85(8):824-7.
1996: Meenu Wadhwa; Chris Bird; Jan Fagerberg; R Gaines-Das; Peter Ragnhammar; Håkan Mellstedt; Robin Thorpe
Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy.
Clinical and experimental immunology 1996;104(2):351-8.
1996: Jan Fagerberg; Peter Ragnhammar; Maria Liljefors; A L Hjelm; Håkan Mellstedt; Jan-Erik Frödin
Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.
Cancer immunology, immunotherapy : CII 1996;42(2):81-7.
1995: Jan Fagerberg; C Rubio; I Gresser; R Kuylenstierna; Eva Munck-Wikland; Hans Strander
Interferon-alpha/beta can impede development of carcinogen-induced squamous-cell tumors in the esophagus of C57B1 mice.
International journal of cancer. Journal international du cancer 1995;62(1):103-6.
1995: Peter Ragnhammar; Jan Fagerberg; Jan-Erik Frödin; Peter Wersäll; L O Hansson; Håkan Mellstedt
Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.
Cancer immunology, immunotherapy : CII 1995;40(6):367-75.
1995: Jan Fagerberg; M Steinitz; Hans Wigzell; P Askelöf; Håkan Mellstedt
Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(11):4773-7.
1995: Carlos A Rubio; M Sveander; Eva Munck-Wikland; H Witt; Jan Fagerberg
Evaluation of the protracted stress in the esophageal mucosa of rats.
In vivo (Athens, Greece) 1995;9(3):187-91.
1995: Jan Fagerberg; A L Hjelm; Peter Ragnhammar; Jan-Erik Frödin; Hans Wigzell; Håkan Mellstedt
Tumor regression in monoclonal antibody-treated patients correlates with the presence of anti-idiotype-reactive T lymphocytes.
Cancer research 1995;55(9):1824-7.
1995: A L Hjelm; Peter Ragnhammar; Jan Fagerberg; I Magnusson; J E Frodin; R Svanstrom; Jayant D Shetye; Håkan Mellstedt; J P Wersall
Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma. A phase II study.
Cancer biotherapy 1995;10(1):5-12.
1994: Jayant D Shetye; T Mathiesen; Jan Fagerberg; C Rubio
Ear tumours induced by experimental carcinogenesis in the rat: excision prevents early death.
International journal of colorectal disease 1994;9(3):125-7.
1994: Dag Stockeld; Jan Fagerberg; Lars Backman; R Lewensohn; Lars Granström
[Views on handling of esophageal cancer. Better prognosis with new methods?].
Läkartidningen 1994;91(22):2243-6.
1994: Jan Fagerberg; Jan-Erik Frödin; Peter Ragnhammar; M Steinitz; Hans Wigzell; Håkan Mellstedt
Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). II. Is induction of anti-idiotype reactive T cells (T3) of importance for tumor response to mAb therapy?
Cancer immunology, immunotherapy : CII 1994;38(3):149-59.
1994: Jan Fagerberg; Dag Stockeld; Rolf Lewensohn
Combined treatment modalities in esophageal cancer. Should chemotherapy be included?
Acta oncologica (Stockholm, Sweden) 1994;33(4):439-50.
1993: Jan Fagerberg; Jan-Erik Frödin; Hans Wigzell; Håkan Mellstedt
Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1). I. May induction of ab1-reactive T cells and anti-anti-idiotypic antibodies (ab3) lead to tumor regression after mAb therapy?
Cancer immunology, immunotherapy : CII 1993;37(4):264-70.
1993: Jan Fagerberg; Jan-Erik Frödin; Peter Ragnhammar; M Steinitz; Hans Wigzell; Håkan Mellstedt
Immunization effect of monoclonal antibodies against tumor-associated antigens during cancer treatment.
Annals of the New York Academy of Sciences 1993;690():337-9.
1993: Peter Ragnhammar; Jan Fagerberg; Jan-Erik Frödin; A L Hjelm; C Lindemalm; I Magnusson; Giuseppe Masucci; Håkan Mellstedt
Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
International journal of cancer. Journal international du cancer 1993;53(5):751-8.
1993: C Rubio; Eva Munck-Wikland; Jan Fagerberg; Hans Strander; R Kuylenstierna; C Kruel
Further studies on the carcinogenic-free interval following exposure in experimental esophageal tumorigenesis.
In vivo (Athens, Greece) 1993;7(1):81-4.
1993: J P Wersäll; Giuseppe Masucci; A L Hjelm; Peter Ragnhammar; Jan Fagerberg; Jan-Erik Frödin; K Merk; C Lindemalm; K Ericson; B Kalin
Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma.
Medical oncology and tumor pharmacotherapy 1993;10(3):103-11.
1991: Håkan Mellstedt; Jan-Erik Frödin; Giuseppe Masucci; Peter Ragnhammar; Jan Fagerberg; A L Hjelm; Jayant D Shetye; Peter Wersäll; Anders Osterborg
The therapeutic use of monoclonal antibodies in colorectal carcinoma.
Seminars in oncology 1991;18(5):462-77.
1991: Håkan Mellstedt; Jan-Erik Frödin; P Biberfeld; Jan Fagerberg; R Giscombe; A Hernandez; Giuseppe Masucci; S L Li; M Steinitz
Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to the "internal image of the antigen" (ab2).
International journal of cancer. Journal international du cancer 1991;48(3):344-9.
1991: Giuseppe Masucci; Peter Ragnhammar; Jan-Erik Frödin; A L Hjelm; Peter Wersäll; Jan Fagerberg; Anders Osterborg; Håkan Mellstedt
Chemotherapy and immunotherapy of colorectal cancer.
Medical oncology and tumor pharmacotherapy 1991;8(3):207-20.
1991: Håkan Mellstedt; Jan-Erik Frödin; Peter Ragnhammar; Giuseppe Masucci; A Ljungberg; A L Hjelm; Jan Fagerberg; C Lindemalm; Anders Osterborg; Peter Wersäll
Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).
Acta oncologica (Stockholm, Sweden) 1991;30(8):923-31.